{
  "id": 7550141,
  "title": "Mizuho raises Immix Biopharma stock price target to $26 on expansion",
  "url": "https://urgent.news/2026/09/15/mizuho-raises-immix-biopharma-stock-price-target-to-26-on-expansion",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-15T12:44:47.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/analyst-ratings/mizuho-raises-immix-biopharma-stock-price-target-to-26-on-expansion-93CH-4901722"
  },
  "original_language": "en",
  "account": null,
  "summary": "Mizuho has raised its price target for Immix Biopharma (IMMX) stock to $26 from $15, maintaining an Outperform rating. The firm now anticipates a potential second indication for NXC-201 in the first-line AL amyloidosis setting, which could generate a peak revenue of over $2 billion. A Phase 3 study for this indication is planned for the first half of 2027, building on the strong Phase 2 data seen previously. Immix Biopharma's stock currently trades at $12.21 with a market cap of $873.5 million, though the company may be overvalued relative to its Fair Value according to InvestingPro analysis. The updated price target implies an upside of more than 100%. The firm has named Immix Biopharma its top September pick, reflecting high conviction in the upcoming data update from the Phase 2 NEXICART-2 study for NXC-201 in relapsed/refractory AL amyloidosis.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}